ePharmaSolutions Joins the WIRB-Copernicus Group
New addition expands WCG’s eClinical offerings for improving clinical trial start-up and management
PRINCETON, N.J., Sept. 24, 2014 – WIRB-Copernicus Group (WCG), the world’s largest provider of regulatory and ethical review services for clinical research, announced today that ePharmaSolutions (ePS) has joined its group of companies. Based near Philadelphia, PA, ePS is a leading provider of eClinical solutions and technology-enabled services that improve the conduct of clinical trials. Its proprietary solutions, including a cloud-based enterprise Clinical Trial Portal (CTP) and Electronic Trial Master File (eTMF), are used by 350,000 clinical research professionals in 130 countries who benefit from the improved coordination of study start up, site management, and regulatory document control.
“We are delighted to welcome ePharmaSolutions into the WCG family of companies. WCG and ePharmaSolutions share a powerful vision of how to improve clinical research trials – a cornerstone in the mission of WCG,” said WCG Chairman and CEO Donald A. Deieso, Ph.D. “Using ePS’ leading technology-driven solutions to assure that the activities of trial sites are coordinated, well informed, and efficiently managed will result in significant benefits to pharmaceutical companies, contract research organizations (CROs), institutions, and subjects.”
“Joining WCG will fulfill our company’s enormous potential as a beneficial force in the conduct of clinical trials,” said ePS Founder and CEO Lance Converse. “We look forward to contributing our technology and clinical support services to the broader mission of WCG – industry transformation,” he added. September has been an important month for our company; in addition to the WCG transaction, we were pleased to have been chosen as the winner of the ‘Disruptive Innovator of the Year’ award during the fourth annual Dpharm: Disruptive Innovations to Advance Clinical Trials conference – a recognition by leading industry professionals of the value of our work. ”
Like the other companies within WCG, ePharmaSolutions will continue to operate independently at its current locations, and will retain both its leadership and brand. WCG will support ePharmaSolutions as it continues to expand its platform solution with access to capital, complementary clinical expertise, corporate support, and integration of its technologies within the WCG family of companies.
ePharmaSolutions joins Western IRB (WIRB), Copernicus Group IRB, Midlands IRB, Aspire IRB, New England IRB, and IRBNet as a member of the WCG family of companies.
Financial details about the transaction were not disclosed.
About The WIRB-‐Copernicus Group
The WIRB-Copernicus Group (WCG) is the world’s largest and most trusted provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG’s solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials.
WCG is proud to serve the individuals on the frontlines of science and medicine, and the organizations that strive to develop new products and therapies to improve the quality of human health. It is our role to empower them to accelerate advancement, while ensuring that the risks of progress never outweigh the value of human life.
For more information, please visit www.wcgclinical.com.
Download the Press Release